Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: A phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

The Lancet

Volumn 385, Issue 9979, 2015, Pages 1738-1747

  Dawson, Rodney ^a   Diacon, Andreas H ^b,c   Everitt, Daniel ^b,d   Van Niekerk, Christo ^e   Donald, Peter R ^b   Burger, Divan A ^f,g   Schall, Robert ^f,g   Spigelman, Melvin ^d   Conradie, Almari ^e   Eisenach, Kathleen ^h   Venter, Amour ^c   Ive, Prudence ⁱ   Page Shipp, Liesl ^j   Variava, Ebrahim ⁱ   Reither, Klaus ^k,l   Ntinginya, Nyanda E ^m   Pym, Alexander ⁿ   Von Groote Bidlingmaier, Florian ^c   Mendel, Carl M ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c TASK APPLIED SCIENCE   (South Africa)

^d GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^e Global Alliance for TB Drug Development   (South Africa)

^f UNIVERSITY OF THE FREE STATE   (South Africa)

^g IQVIA   (United States)

^h UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j AURUM INSTITUTE   (South Africa)

^k SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^l IFAKARA HEALTH INSTITUTE   (Tanzania)

^m NIMRMbeya Medical Research Centre   (Tanzania)

ⁿ UNIVERSITY OF KWAZULU NATAL   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PRETOMANID; PYRAZINAMIDE; RIFAMPICIN; 2-NITRO-6-(4-(TRIFLUOROMETHOXY)BENZYLOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE; NITROIMIDAZOLE DERIVATIVE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIC50; MIC90; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM SMEAR; VOMITING; ADOLESCENT; BACTERIAL COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; MICROBIOLOGY; MULTICENTER STUDY; SOUTH AFRICA; SPUTUM; TANZANIA; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; FLUOROQUINOLONES; HUMANS; ISONIAZID; MALE; NITROIMIDAZOLES; PYRAZINAMIDE; RIFAMPIN; SOUTH AFRICA; SPUTUM; TANZANIA; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84929030774     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62002-X     Document Type: Article

References (21)

1. A Zumla, M Raviglione, R Hafner, F von Reyn Tuberculosis N Engl J Med 368 2013 745 755
2. GB Migliori, G Sotgiu, NR Gandhi et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis Eur Respir J 42 2013 169 179
3. AI Zumla, SH Gillespie, M Hoelscher et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects Lancet Infect Dis 14 2014 327 340
4. E Nuermberger, S Tyagi, K Tasneen et al. Powerful bactericidal and sterilizing activity of a regimen containing PA824 moxifloxacin, and pyrazinamide in a murine model of tuberculosis Antimicrob Agents Chemother 52 2008 1522 1524
5. AH Diacon, R Dawson, F von Groote-Bidlingmaier et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial Lancet 380 2012 986 993
6. GR Davies, R Brindle, SH Khoo, LJ Aarons Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment Antimicrob Agents Chemother 50 2006 3154 3156
7. R Rustomjee, AH Diacon, J Allen et al. Early bactericidal activity and pharmacokinetics of the diarylquinoiline TMC207 in treatment of pulmonary tuberculosis Antimicrob Agents Chemother 52 2008 2831 2835
8. AH Diacon, R Dawson, M Hanekom et al. Early bactericidal activity and pharmacokinetics of PA824 in smear-positive tuberculosis patients Antimicrob Agents Chemother 54 2010 3402 3407
9. International Union Against Tuberculosis and Lung Disease Priorities for tuberculosis bacteriology services for low-income countries 2nd edn. 2007 International Union Against Tuberculosis and Lung Disease Paris http://www.tbrieder.org/publications/books-english/red-book.pdf (accessed Feb 3, 2015).
10. AH Diacon, JS Maritz, A Venter et al. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents Eur J Microbiol Clin Med 29 2010 1561 1565
11. NIAID Division of Microbiology and Infectious Diseases (DMID) Adult toxicity table. November, 2007 draft http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidadulttox.pdf (accessed Feb 3, 2015).
12. R Rustomjee, C Lienhardt, T Kanyok et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis Int J Tuberc Lung Dis 12 2008 128 138
13. DA Burger, R Schall A Bayesian non-linear mixed effects regression model for the characterisation of early bactericidal activity of tuberculosis drugs J Biopharm Stat 2014 10.1080/10543406.2014.971170 published online Oct 16.
14. W Fox, GA Ellard, DA Mitchison Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986 Int J Tuberc Lung Dis 3 1999 S231 S279
15. D Sloan, G Davies Serial sputum colony counting in drug development PR Donald PD van Helden Antituberculosis Chemotherapy 2011 Karger Basel 227 234
16. PPJ Phillips, K Fielding, AJ Nunn An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse PLoS One 8 2013 e63840
17. W Burman, S Goldberg, JL Johnson et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis Am J Respir Crit Care Med 174 2006 331 338
18. MB Conde, A Efron, C Loredo et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomized, controlled phase II trial Lancet 373 2009 1183 1189
19. SE Dorman, JL Johnson, S Goldberg et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis Am J Respir Crit Care Med 180 2009 273 280
20. SH Gillespie, AM Crook, TD McHugh et al. Four-month moxifloxacin-based regimens for drug sensitive tuberculosis N Engl J Med 2014 10.1056/NEJMoa1407426 published online Sept 7.
21. H Li, J Chen, M Zhou et al. Rapid detection of Mycobacterium tuberculosis and pyrazinamide susceptibility related to pncA mutations in sputum specimens through an integrated gene-to-protein function approach J Clin Microbiol 52 2014 260 267